medigraphic.com
ISSN 2992-779X (Digital)
ISSN 2007-6452 (Impreso)

2015, Número 1

<< Anterior Siguiente >>

Investigación en Discapacidad 2015; 4 (1)


Brote de Ébola 2014 en África Occidental y sus riesgos para México

Ortega E, Barrón BL

Idioma: Español
Referencias bibliográficas: 30
Paginas: 9-15
Archivo PDF: 270.12 Kb.


RESUMEN

La fiebre hemorrágica por el virus Ébola es una enfermedad de elevada mortalidad reportada principalmente en África con 24 brotes hasta la fecha. Actualmente se presenta el brote más grande y extendido del que se tiene registro. La presencia de algunos casos de Ébola en Estados Unidos y España pone en alerta máxima a las autoridades de salud de todo el mundo. Se considera que el riesgo de que se dé un brote de esta enfermedad en México es mínimo; sin embargo, es conveniente estar alerta ante la aparición de casos importados. Por lo anterior, en este artículo se hace una revisión de este brote y sus implicaciones para nuestro país.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM. Fields virology. 6 ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013: pp. 923-956.

  2. Viral zone: Ebola virus molecular biology. Suiza: 2014. [Enero de 2015]. Disponible en: http://www.viralzone.expasy.org

  3. Alvarez CP, Lasala F, Carrillo J, Muñiz O, Corbí AL, Delgado R. C-type lectins DC-SING and L-SING mediate cellular entry by Ebola virus in cis and in trans. J Virol. 2002; 67: 6841-6844.

  4. Nanbo A, Masaki I, Watanabe S, Noda T, Takahashi K, Neumann G et al. Ebolavirus is internalized into host cells via micropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 2010; 6: e1001121.

  5. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005; 438: 575-576.

  6. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya, Sanchez A. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infectious Dis. 2007; 196: S12-147.

  7. Ströher U, West E, Bugany H, Klenk HD, Schnittler HJ et al. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol. 2001; 75: 11025-11033.

  8. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2014; 235: 153-174. doi: 10.1002/path.4456.

  9. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg diseases. Disease Models and Mechanisms. 2009; 2: 12-17.

  10. Kortepetern MK, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infectious Diseases. 2011; 204: S810-S816.

  11. Beize S, Pannetier D, Pharm D, Oestereich L, Rieger T, Koivogui L et al. Emergence of Zaire Ebola virus disease in guinea. N Egl J Med. 2014; 371: 1418-1425.

  12. Gire SK, Goba A, Andersen KG, Sealfon RSG, Park DJ, Kanneh L et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014; 345: 1369-1372.

  13. World Health Organization. Ebola response roadmap situation report. [5 de abril 2015]. Disponible en: http://www.who.int/csr/disease/ebola/situation-reports/en/

  14. Chan M. Ebola virus diseases in west Africa-no early end to the outbreak. N Engl J Med. 2014; 371: 1183-1185.

  15. Wesolowski A, Buckee CO, Bengtsson L, Wetter E, Lu X, Tatem AJ. Commentary: containing the Ebola outbreak-the potential and challenge of mobile network data. PLoS Curr. 2014; doi: 10.1371/currents.outbreaks.0177e7fcf52217b8b634376e2f3efc5e.

  16. Frieden TR, Damon I, Bell BP, Kenyon T, Nichol S. Ebola 2014-new challenges, new global response and responsibility. 2014; 371: 1177-1180.

  17. Philips M, Markham A. Ebola: a failure of international collective action. The Lancet. 2014; 384: 1181.

  18. Dudas G, Rambaut A. Phylogenetic analysis of guinea 2014 EBOV Ebolavirus outbreak. PLoS Curr. 2014; doi: 10.1371/currents.outbreaks.84eefe5ce43ec9dc0bf0670f7b8b417d.

  19. Centers for Disease Control and Prevention. 2014 Ebola outbreak in Democratic Republic of the Congo. [Enero 2015]. Disponible en: http://www.cdc.gov/vhf/ebola/outbreaks/drc/2014-august.html

  20. Leroy EM, Labouba I, Maganga GD, Berthet N. Ebola in West Africa: the outbreak able to change many things. Clin Microbiol Infect. 2014; doi: 10.1111/1469-0691.12781.

  21. Gulland A. More health staff are needed to contain Ebola outbreak, warns WHO. BMJ. 2014; 349: g5485.

  22. Rivers CM, Lofgren ET, Marathe M, Eubank S, Lewis BL. Modeling the Impact of Interventions on an Epidemic of Ebola in Sierra Leone and Liberia. PLoS Curr. 2014; doi: 10.1371/currents.outbreaks.fd38dd85078565450b0be3fcd78f5ccf

  23. Hampton T. Largest-ever outbreak of Ebola virus disease thrusts experimental therapies, vaccines into spotlight. JAMA. 2014; 312: 987-989.

  24. Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013; 199: 199ra113.

  25. Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375: 1896-1905.

  26. Dirección General de Epidemiología de la Secretaría de Salud. Lineamientos estandarizados para la vigilancia epidemiológica y diagnóstico por laboratorio de enfermedad por el virus del Ébola. 2014.

  27. WHO. Technical specifications for PPE equipment to be used by health workers providing clinical care for patients. Disponible en: http://apps.who.int/iris/bitstream/10665/137411/1/WHO_EVD_Guidance_SpecPPE_14.1_eng.pdf?ua=1.

  28. Feldmann H, Jones SM, Daddario-DiCaprio KM, Giesbert JB, Ströher U, Grolla A et al. Effective post-exposure treatment of Ebola infection. PloS Pathog. 2007; 3 (1): e2.

  29. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, van Tongeren SA et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014; 508: 402-405.

  30. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011; 85: 4222-4233.




2020     |     www.medigraphic.com